This exclusive report dives deep into the global Nuclear Medicine Market, providing a thorough analysis. It looks at how AI is enhancing radiopharmaceutical diagnostics, the regulatory requirements for precision oncology and offers a variety of regional insights. Key components include competitive benchmarking, market dynamics and assessments of cutting-edge theranostics and isotope-integrated lifecycles. The global Nuclear Medicine Market size was valued at US$ 18.79 Billion in 2025 and is poised to grow from US$ 20.22 Billion in 2026 to US$ 36.33 Billion by 2033, growing at a CAGR of 10.16% in the forecast period (2026-2033). The report encompasses detailed segment analysis by type, application, and geography, with particular emphasis on emerging theranostic platforms and AI-driven imaging reconstruction technologies. Strategic insights into regulatory frameworks, competitive positioning, and market opportunities are provided across all major regions, enabling stakeholders to identify growth trajectories and investment priorities.
Market Size (2026)
$18.79B
Projected (2033)
$36.33B
CAGR
10.16%
Published
May 2026
Select User License
Selected
PDF Report
USD 4,900
USD 3,200
The Nuclear Medicine Market is valued at $18.79B and is projected to grow at a CAGR of 10.16% during 2026 - 2033. North America holds the largest regional share, while Asia-Pacific (12.55%–17.1% CAGR) is the fastest-growing market.
Study Period
2020 - 2033
Market Size (2026)
$18.79B
CAGR (2026 - 2033)
10.16%
Largest Market
North America
Fastest Growing
Asia-Pacific (12.55%–17.1% CAGR)
Market Concentration
Medium
*Disclaimer: Major Players sorted in no particular order
Source: Claritas Intelligence — Primary & Secondary Research, 2026. All market size figures in USD unless otherwise stated.
Global Nuclear Medicine market valued at $18.79B in 2026, projected to reach $36.33B by 2033 at 10.16% CAGR
Key growth driver: Increasing adoption of imaging and targeted radiopharmaceutical therapies for diagnosis and treatment planning (High, +3.5% CAGR impact)
North America holds the largest market share, while Asia-Pacific (12.55%–17.1% CAGR) is the fastest-growing region
AI Impact: Artificial Intelligence is really changing the Nuclear Medicine Market. It is taking the way of using isotopes to make images and turning it into a system that uses Artificial Intelligence to make it smarter.
12 leading companies profiled including Eckert & Ziegler, Mallinckrodt, Cardinal Health and 9 more
Artificial Intelligence is really changing the Nuclear Medicine Market. It is taking the way of using isotopes to make images and turning it into a system that uses Artificial Intelligence to make it smarter. The biggest change is that it is making Deep Learning Reconstruction and Quantitative Imaging Analytics better. This means that of just looking at the images the systems can now automatically figure out what is going on. These systems use Artificial Intelligence networks that are built into PET/CT and SPECT/CT scanners. They can look at the data in real time and make the images clearer.
They can even find problems that are hard to see. By 2026 these systems will be able to adjust the treatment plan based on how the patient's responding. This means that the treatment will be tailored to each patient, which's a big improvement over the old way of doing things. Artificial Intelligence is also helping the sector. It is making sure that the right isotopes get to the places at the right time. Artificial Intelligence is being used to track the isotopes and make sure they do not go to waste.
In 2026 Artificial Intelligence will be used to plan the delivery routes for the isotopes. Artificial Intelligence is also helping to find drugs. It is giving people a view of the pipeline and helping them figure out which drugs to test next. Artificial Intelligence can even simulate how the drugs will work, which makes it easier to develop ones. All of this means that the Nuclear Medicine Market is going to be a part of the move towards more precise and efficient healthcare solutions. Artificial Intelligence is really making a difference, in the Nuclear Medicine Market.
The nuclear medicine market has transformed into a vital part of precision oncology and neurology, moving away from one-size-fits-all treatments to more precise molecular interventions. Today, we're witnessing the rise of radiotheranostics, where a single radioactive agent is utilized to both detect and treat specific cellular targets. This shift is largely influenced by the success of targeted radioligand therapies, which enable the delivery of high-energy radiation directly to cancer cells while protecting the surrounding healthy tissue. This has firmly established nuclear medicine as a primary option for complex prostate and neuroendocrine conditions.
A major trend is the use of artificial intelligence in molecular imaging, which enhances the interpretation of PET and SPECT scans to catch neurodegenerative changes long before any physical symptoms show up. Manufacturers are focusing on ramping up non-reactor isotope production, using advanced cyclotrons to maintain a steady supply of short-lived isotopes. Plus, we're seeing a strategic merging of diagnostics and therapeutics, with healthcare systems investing in integrated shielded infusion suites. This professional environment reflects a market that has matured with molecular-level precision and streamlined regulatory processes, positioning nuclear medicine as a vital data-driven component of global specialized healthcare.
| Year | Market Size (USD Billion) | Period |
|---|---|---|
| 2025 | $18.79B | Historical |
| 2026 | $20.40B | Forecast |
| 2027 | $22.16B | Forecast |
| 2028 | $24.06B | Forecast |
| 2029 | $26.13B | Forecast |
| 2030 | $28.37B | Forecast |
| 2031 | $30.81B | Forecast |
| 2032 | $33.46B | Forecast |
| 2033 | $36.33B | Forecast |
Source: Claritas Intelligence — Primary & Secondary Research, 2026. All market size figures in USD unless otherwise stated.
Base Year: 2025The nuclear medicine market is getting a lot of support because doctors are using imaging and targeted radiopharmaceutical therapies more and more for diagnosis and treatment planning.
Today, we're witnessing the rise of radiotheranostics, where a single radioactive agent is utilized to both detect and treat specific cellular targets.
A major trend is the use of artificial intelligence in molecular imaging, which enhances the interpretation of PET and SPECT scans to catch neurodegenerative changes long before any physical symptoms show up.
Nuclear medicine allows doctors to make treatment plans that are specific to each patient based on what is going on in their body.
One of the challenges is that there are not enough special facilities and skilled people to handle and give radiopharmaceuticals to patients.
It can be hard to get all the different teams to work together like the people who do the imaging the people who make the radiopharmaceuticals and the doctors.
Some doctors may not be as familiar with medicine, which can also affect how often it is used, especially in places where other types of diagnostic tools are used more often.
There are also some opportunities for nuclear medicine to grow. One of the opportunities is that it can be used in more areas of medicine and it can be a part of bigger treatment plans. The fact that doctors are starting to use theranostics, which's when they use diagnostic imaging and targeted therapy together is opening up new ways to plan and manage treatments. The fact that there are outpatient imaging centers and that specialists are working together more can also help more people get access, to nuclear medicine.
There is also a chance for nuclear medicine to be used more in areas of therapy which can help it keep evolving as a part of precision healthcare and nuclear medicine.
| Region | Market Share | Growth Rate |
|---|---|---|
| North America | 34.5% | 14.78%–15.6%% CAGR |
| Europe | 15.1% | 11.4%% CAGR |
| Asia Pacific | 11.6% | 12.55%–17.1%% CAGR |
| Latin America | 11.4% | 4.1%–5.9%% CAGR |
| Middle East & Africa | 27.4% | 5.4%–7.2%% CAGR |
Source: Claritas Intelligence — Primary & Secondary Research, 2026.
Eckert & Ziegler Mallinckrodt Cardinal Health GE Healthcare Jubilant Life Sciences Ltd Nordion (Canada), Inc. A The Australian Nuclear Science and Technology Organization Eczacıbaşı-Monrol Lantheus Medical Imaging, Inc The institute for radioelements (IRE) NTP Radioisotopes SOC Ltd. These leading organizations compete across radiopharmaceutical production, imaging equipment manufacturing, and isotope supply chain management. Cardinal Health expanded Actinium-225 production capacity in April 2026 to support growing demand for novel cancer therapies. 26 in March 2026, demonstrating continued investment in diagnostic imaging solutions. Market consolidation reflects increasing capital requirements for cyclotron infrastructure, regulatory compliance, and theranostic platform development.
At ACC.26, GE HealthCare (Nasdaq: GEHC) will showcase some of its boldest ideas yet that support clinicians across the cardiology care pathway - from diagnosis to treatment to procedural guidance and monitoring. Its latest cardiology innovations, featuring advancements within diagnostic cardiology, CT, image guiding solutions, ultrasound, cloud, and software solutions, are helping clinicians deliver critical precision care throughout the patient journey.
Cardinal Health (NYSE:CAH) today announced a significant expansion of its Actinium-225 (Ac-225) production capabilities at the company's Center for Theranostics Advancement (CTA) in Indianapolis, Indiana. The addition of a high-capacity production line to its Drug Master File (DMF) will substantially increase Cardinal Health's supply of cGMP-compliant Ac-225 for use in investigational therapeutic drug products and future commercial manufacturing novel therapies.
The nuclear medicine market was valued at USD 18.79 billion in 2025 and is forecasted to reach USD 36.33 billion by 2033. This represents a robust expansion driven by increasing adoption of precision medicine and radiotheranostics in clinical settings globally. See our market size analysis →
The nuclear medicine market is growing at a compound annual growth rate (CAGR) of 10.16% from 2026 to 2033. Key growth drivers include the rise of targeted radioligand therapies, increased cancer prevalence, and advancements in molecular imaging technologies for precision oncology. See our growth forecast → See our key growth drivers →
Radiotheranostics and targeted radioligand therapies represent the fastest-growing segments within the nuclear medicine market. These technologies enable simultaneous detection and treatment of specific cellular targets, particularly in oncology and neurology applications, driving overall market expansion. See our segment analysis →
North America currently dominates the nuclear medicine market with the largest market share. However, Asia-Pacific is the fastest-growing region, with projected CAGR of 12.55–17.1%, driven by increasing healthcare infrastructure investment, rising cancer incidence, and expanding radiopharmaceutical manufacturing capacity. See our growth forecast → See our geography analysis →
Leading companies in the nuclear medicine market include Eckert & Ziegler, Mallinckrodt, Cardinal Health, GE Healthcare, and Jubilant Life Sciences Ltd. These players dominate through radiopharmaceutical production, diagnostic imaging equipment, and theranostic solutions. See our competitive landscape →
Primary growth drivers include the shift toward precision medicine and personalized cancer treatments, particularly through radiotheranostics and targeted radioligand therapies. Additionally, increasing prevalence of cancer and neurological disorders, combined with technological advances in molecular imaging, significantly accelerates market expansion. See our key growth drivers →
Major challenges include stringent regulatory requirements for radiopharmaceutical approval and manufacturing, high development costs for new therapeutic agents, and supply chain complexities for radioactive materials. Additionally, reimbursement limitations and radiation safety concerns pose barriers to market growth. See our market challenges →
Significant opportunities include integration of artificial intelligence in diagnostic imaging and treatment planning, expansion of radiopharmaceutical manufacturing in emerging Asian markets, and development of novel theranostic agents targeting underserved cancer types. Growing adoption of nuclear medicine in precision oncology pathways presents substantial growth potential. See our emerging opportunities →
How this analysis was conducted
Primary Research
Secondary Research
Access detailed analysis, data tables, and strategic recommendations.